Aktiesnakken — August 2012
-
det er sku en interessant mand til den post
-
en meget erfaren industri mand, åh jeg kender ham godt fra GN tiden
-
han er en god kommunikator. Det har han altid været
-
det står altid meget klart hvad hans budskab er.
-
tjek denne: http://www.proinvestor.com/boards/60312/
-
formand for skraldespand trækker sig http://www.business.dk/finans/kruse-petersen-traekker-sig-som-formand-for-finansiel-stabilitet
-
og hvilken spand
-
-
SAR650984 (Sanofi) - This is a CD38 naked antibody that entered phase I in mid-2010. Sanofi did not report results from this trial but Genmab (GEN.CO) reported excellent results for its CD38 antibody, daratumumab. Genmab's antibody looks extremely active as a single agent in multiple myeloma with a response rate of 42% and a good safety profile. Sanofi's SAR650984 looks similar to daratumumab in preclinical testing, so it is likely that Sanofi is also seeing promising results
-
ikke hotte på den gode måde ihvertfald
-
fodbold det er om muligt endnu værre end biotek. Det er zero return
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind